Buy ARA-290 (16mg) – Premium Research Peptide for Tissue Protection Studies
Welcome to Liaocheng Yixin Company, your trusted source to buy ARA-290 16mg for research. As a licensed peptide synthesis manufacturer operating from our facility in Shandong Province, China, we provide high-quality research compounds for the global scientific community.
ARA-290 (also known as Cibinetide) is a synthetic 11-amino-acid peptide derived from the tertiary structure of the helix B region of erythropoietin (EPO). Unlike full-length EPO, it is engineered to selectively target the innate repair receptor (IRR) without engaging erythropoietic pathways, thereby avoiding hematopoietic side effects. Our ARA-290 16mg for research offers investigators a reliable, high-purity compound for neuroinflammatory, tissue-protective, and metabolic studies.
What is ARA-290?
ARA-290 is a synthetic peptide that mimics the three-dimensional structure of the helix B surface domain of erythropoietin. It binds selectively to the non-hematopoietic EPO receptor complex—believed to be a heterodimer of EPOR and the β-common receptor (CD131)—sometimes referred to as the innate repair receptor or IRR.
Key identifiers:
-
Synonyms: Cibinetide, Helix B Surface Peptide (HBSP), PH-BSP
-
Molecular Weight: ~1,873 Da
-
Sequence: Ala-Glu-Gly-Val-Leu-Ser-Glu-Lys-Ala-Leu-Leu-Glu-Leu-Lys-Gly-Glu
-
Purity: ≥98% verified by HPLC
Mechanism of Action in Research
ARA-290 operates through a distinctive mechanism that combines tissue protection with a clean safety profile.
Innate Repair Receptor (IRR) Activation
ARA-290 selectively activates the IRR—a heterodimeric receptor composed of EPOR and CD131 that is rapidly up-regulated locally following tissue injury. This targeted activation initiates anti-inflammatory and pro-survival signaling cascades, including downregulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and suppression of NF-κB activation.
TRPV1 Antagonism and Pain Signaling
Beyond immune modulation, ARA-290 directly targets peripheral nociceptors by specifically inhibiting the TRPV1 ion channel, a key integrator of nociception and neurogenic inflammation. This direct analgesic effect is distinct from its anti-inflammatory actions.
Tissue Protection and Regeneration
ARA-290 activates the JAK-STAT and PI3K/Akt signaling pathways, preventing apoptosis in neural and endothelial cells while promoting tissue regeneration. It has been shown to suppress PECAM-1, VCAM-1, and ICAM-1 expression, reducing microvascular thrombosis and progressive tissue necrosis.
Scientific Research Applications
Neuropathic Pain and Neuropathy Research
Preclinical studies demonstrate that ARA-290 produces long-term relief of tactile and cold allodynia for up to 15 weeks in rat models of peripheral nerve injury. Phase 2 clinical trials are evaluating its effects on small fiber neuropathy in patients with sarcoidosis and type 2 diabetes, with endpoints including changes in corneal nerve fiber density, intraepidermal nerve fiber density (IENFD), and pain scores.
Neuroinflammation and Immune Modulation
ARA-290 has been shown to reduce immune cell activity and ameliorate symptoms in mouse models of experimental colitis. It is studied for its capacity to modulate microglia activation and downregulate pro-inflammatory pathways in the central nervous system.
Metabolic Research
In preclinical models, ARA-290 has demonstrated improvements in glucose tolerance and reduced HbA₁c in diabetic models, potentially through direct effects on pancreatic β-cell function.
Why Choose Liaocheng Yixin Company?
When you buy ARA-290 16mg for research, quality and reliability are paramount. Here’s why researchers trust us:
Manufacturer-Direct Quality
We are a legitimate, licensed peptide synthesis company with a physical headquarters in Shandong Province, China. Our facility maintains strict quality control standards.
Verified Purity Standards
Every batch undergoes rigorous testing using HPLC analysis. Our ARA-290 meets ≥98% purity standards. Certificates of Analysis are available upon request.
Research-Grade Specifications
-
Purity: ≥98% verified by HPLC
-
Appearance: White lyophilized powder
-
Storage: Store powder at -20°C in a sealed, desiccated container, protected from light and moisture. Reconstituted solutions should be stored at 2-8°C.
-
Form: Lyophilized powder for research use
Quality Assurance & Testing
Every batch undergoes comprehensive quality control:
-
Synthesis by experienced chemists using solid-phase peptide synthesis
-
Purification via preparative HPLC
-
Analysis using HPLC for purity verification
-
Mass Spectrometry for molecular weight confirmation
-
Packaged under sterile conditions for research use
: What is ARA-290 and how does it work in research?
A: ARA-290 (Cibinetide) is an 11-amino-acid peptide derived from the helix B region of erythropoietin that selectively activates the innate repair receptor (IRR) without hematopoietic effects. It modulates inflammation, promotes tissue protection, and directly antagonizes TRPV1 channels involved in pain signaling.
: What are the key research applications for ARA-290?
A: ARA-290 is used in neuropathic pain and neuropathy studies, neuroinflammation research, immune modulation investigations, and metabolic research.
: Is ARA-290 erythropoietic?
A: No. ARA-290 is specifically engineered to be non-erythropoietic, avoiding the hematopoietic side effects associated with full-length EPO.
: What purity level can I expect?
A: All batches are tested to ensure ≥98% purity by HPLC analysis. Certificates of Analysis are available upon request.
: Is this product for human use?
A: No. Our ARA-290 is manufactured strictly for research use only (RUO). It is not intended for human consumption or clinical applications.
When you need to buy ARA-290 16mg for research for your neuropathic pain, tissue protection, or metabolic studies, choose a manufacturer that prioritizes quality, transparency, and reliability. Liaocheng Yixin Company combines expert peptide synthesis capabilities with rigorous quality control to deliver research materials you can trust.




Reviews
There are no reviews yet.